{"product_id":"camidanlumab-elisa-kit","title":"Camidanlumab ELISA Kit","description":"\u003cp\u003e\u003cb\u003eSize\u003c\/b\u003e:96T\u003c\/p\u003e\u003cp\u003e\u003cb\u003eApplications\u003c\/b\u003e:ELISA\u003c\/p\u003e\u003cp\u003e\u003cb\u003eAccession\u003c\/b\u003e:P01589\u003c\/p\u003e\u003cp\u003e\u003cb\u003eStability and Storage\u003c\/b\u003e:The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.\u003c\/p\u003e\u003cp\u003e\u003cb\u003eDetection method\u003c\/b\u003e:Colorimetric\u003c\/p\u003e\u003cp\u003e\u003cb\u003eSample type\u003c\/b\u003e:Plasma, Serum\u003c\/p\u003e\u003cp\u003e\u003cb\u003eAssay type\u003c\/b\u003e:Quantitative\u003c\/p\u003e\u003cp\u003e\u003cb\u003eSensitivity\u003c\/b\u003e:0.156 μg\/ml\u003c\/p\u003e\u003cp\u003e\u003cb\u003eRange\u003c\/b\u003e:0.31-5 μg\/mL\u003c\/p\u003e\u003cp\u003e\u003cb\u003eRecovery\u003c\/b\u003e:80-120%\u003c\/p\u003e\u003cp\u003e\u003cb\u003eProperties\u003c\/b\u003e:\u003c\/p\u003e\u003cp\u003e\u003cb\u003eExperimental Procedure\u003c\/b\u003e:\u003c\/p\u003e\u003cp\u003e\u003cb\u003eBackground\u003c\/b\u003e:Camidanlumab tesirine is an antibody-drug conjugate against CD25, an antigen expressed in several malignancies, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). This open-label, dose-escalation and -expansion study (NCT02588092) assessed the safety, activity, pharmacokinetics (PK), and immunogenicity of camidanlumab tesirine in patients with relapsed\/refractory ALL\/AML. A total of 35 patients (34 AML and 1 ALL) were enrolled and received camidanlumab tesirine intravenously at 3-92 μg\/kg once every three weeks (Q3W, n = 26) or 30 or 37.5 μg\/kg every week (QW, n = 9). One dose-limiting toxicity of maculopapular rash occurred in the 30 μg\/kg QW group; the maximum tolerated dose was not reached. No additional safety concerns or adverse events (AEs) of interest were identified. The most common (\u0026gt;10 % of patients) Grade ≥3 treatment-emergent AEs were febrile neutropenia (25.7 %), lymphopenia, neutropenia, thrombocytopenia or fatigue (all 14.3 %), pneumonia, increased gamma-glutamylListase, and hypophosphatemia (each 11.4 %). No signal for serious immune-related AEs such as Guillain-Barré syndrome\/polyradiculopathy was observed and there was no evidence of immunogenicity. PK showed rapid clearance with apparent half-life \u0026lt;2 days for conjugated and total antibody, suggesting that Q3W dosing may be insufficient for therapeutic efficacy, and prompting exploration of a QW schedule. Two patients achieved complete responses with incomplete hematologic recovery; one each at 30 and 37.5 μg\/kg QW. The trial was terminated during dose escalation due to programmatic reasons other than safety. Hence, recommended dose was not determined.\u003c\/p\u003e\u003cp\u003e\u003cb\u003eAlternative Names\u003c\/b\u003e:ADCT-301(unconjugated), HuMax-TAC-ADC, 921618-45-3\u003c\/p\u003e\u003cp\u003e\u003cb\u003eShipping\u003c\/b\u003e:2-8 ℃\u003c\/p\u003e\u003cp\u003e\u003cb\u003eNote\u003c\/b\u003e:For Research Use Only.\u003c\/p\u003e","brand":"GeneBio Systems","offers":[{"title":"Default Title","offer_id":48655941501028,"sku":"DF996028","price":764.95,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0558\/8588\/9636\/files\/no_image_default_image-jpeg_8208beb9-26a5-4be3-b3f0-6530abbd5111.jpg?v=1782808737","url":"https:\/\/www.genebiosystems.com\/en-de\/products\/camidanlumab-elisa-kit","provider":"GeneBio ","version":"1.0","type":"link"}